Vertically Integrated Translational Studies of PDX1 as a Therapeutic Target for Pancreatic Cancer via a Novel Bifunctional RNAi Platform.
Pharmacokinetic Study of Omacetaxine Mepesuccinate Administered Subcutaneously to Patients with Advanced Solid and Hematologic Tumors.
Immune Response and Survival of Refractory Cancer Patients Who Received TGF-β2 Antisense/GM-CSF Gene Modified Autologous Tumor Cell (TAG) Vaccine.
Phase 2 Trial of Erlotinib With or Without PF-3512676 (CPG 7909, a Toll-like Receptor 9 Agonist) in Patients With Advanced Recurrent EGFR-Positive Non-Small Cell Lung Cancer.
Notch1 Activation Up-Regulates Pancreatic and Duodenal Homeobox-1.
Rao DD, Wang Z, Senzer N, Nemunaitis J: RNAi and Personalized Cancer Therapy. Discovery Medicine 2013 Feb; 15(81):101-110.
Phase 2 Trial of Erlotinib With or Without PF-3512676 (CPG 7909, a Toll-like Receptor 9 Agonist) in Patients With Advanced Recurrent EGFR-Positive Non-Small Cell Lung Cancer.
A Phase 1 Trial of Oral Ridaforolimus (AP23573; MK-8669) in Combination With Bevacizumab for Patients With Advanced Cancers.
A First-in-human, Phase 1, Dose-escalation Study of Dinaciclib, a Novel Cyclin-dependent Kinase Inhibitor, Administered Weekly in Subjects with Advanced Malignancies.
Nemunaitis J: Cancer Targeting Vaccines: Surrogate Measures of Activity. Human Vaccines & Immunotherapeutics 2013 Jan;9(1):213-218.